Therapy Areas: AIDS & HIV
Medigen and BlueWillow Biologics Partner to Develop Intranasal Vaccine for SARS-CoV-2
11 November 2020 - - Taiwan-based biopharmaceutical company Medigen Vaccine Biologics Corp (TPEx: 6547.TWO) and US-based biopharmaceutical company BlueWillow Biologics, Inc have forged partnership to develop S-2P-NE-01, a nasal vaccine for SARS-CoV-2, the virus that causes COVID-19, the company said.

While the majority of COVID-19 vaccines in development are delivered via intramuscular injection, research has demonstrated that nasal delivery often the initial site of the infection - can prevent the virus from taking hold in the body.

Preclinical research demonstrated that BlueWillow's nasal vaccine adjuvant combined with Medigen's S-2P spike protein resulted in an extremely high neutralizing antibody response, as well as a superior immunoglobulin A response in both serum and lung secretions samples in mice compared to intramuscular injection of S-2P adjuvanted with alum.

Mucosal immune response is critical in reducing viral nasal colonization and preventing the spread of SARS-CoV-2.

BlueWillow's vaccine technology utilizes a novel oil-in-water nanoemulsion adjuvant to enable intranasal vaccines for challenging diseases and intranasal immunotherapy for food allergies.

The adjuvant includes soybean oil, water and a cationic surfactant cetylpirdinium chloride and is currently in use in the company's clinical-stage anthrax and pandemic flu programs and National Institutes of Health -funded preclinical stage RSV, HSV and peanut immunotherapy programs.

When used with intranasal vaccination, the NE adjuvant elicits both mucosal and systemic immunity.

MVC's subunit vaccine is based on the stable prefusion form of the SARS-CoV-2 recombinant spike protein with global technology license from the US Vaccine Research Center at the National Institutes of Health.

Medigen Vaccine Biologics is a biopharmaceutical company using cell-based technologies for the development of vaccines and biosimilars.

With a goal of national self-sufficiency, MVC also aims to provide vaccines and biopharmaceuticals to meet regional needs and with a desire to help globally against the threats of infectious diseases.

MVC's pipeline includes enterovirus EV71 vaccine, dengue vaccine, and influenza quadrivalent vaccine, which have all entered late clinical stage.

MVC's large-scale production facility is adherent to international PIC/s and GMP requirements.

BlueWillow Biologics is a clinical-stage, privately held biopharmaceutical company focused on developing and commercializing topical antiseptic and anti-infective products and intranasal vaccines using its patented nanotechnology platform.

The platform employs novel oil-in-water nano-droplets for products administered to the skin and nose.

In addition to NanoBio Protect, BlueWillow is currently developing intranasal vaccines that elicit both systemic and mucosal immunity for several respiratory and sexually transmitted infections, including SARS-CoV-2 (COVID-19), RSV, HSV2, pandemic influenza and anthrax, as well as intranasal immunotherapy for peanut allergy and other allergic conditions.


Related Headlines